Kalaris Therapeutics

KLRS

Market cap $183M

Kalaris Therapeutics offers a differentiated approach to neovascular AMD with its lead candidate TH103, leveraging unique molecular engineering for improved efficacy and durability. KLRS's Phase 1a data showed a clinically significant 10-letter visual acuity gain and promising durability, with 31% of patients needing no rescue injection for six months. With $77M in cash and a quarterly burn of ~$12M, KLRS is funded through 2027, enabling execution through the critical Phase 1b/2 data readout expected in H2 2026.

Kalaris Therapeutics, Inc. raised $50M post-positive TH103 trial data, strengthening its cash position to fund TH103 clinical development. KLRS reported improved Q3 '25 results, with a net loss of $11.9M and $77M in cash, supporting operations through 2027. TH103, KLRS's lead asset, showed rapid efficacy and strong safety in Phase 1a, with further Phase 1b/2 data expected in H2 '26.

BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately $50.0 million, before deducting placement agent fees and other offering expenses.

TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection

Berkeley Heights, New Jersey--(Newsfile Corp. - November 24, 2025) - Kalaris Therapeutics, Inc. (Nasdaq: KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Noble Capital Markets 21st Annual Emerging Growth Equity Conference. Details: Type: Company presentation Speakers: Matthew Feinsod, Chief Medical Officer Date: Wednesday, December 3, 2025 Time: 11:30 - 11:55 am ET Location: Florida Atlantic University, Boca Raton, FL Kalaris management will be available for one-on-one meetings during the conference.

Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reported by year end 2025 Phase 1b/2 Multiple Ascending Dose trial currently enrolling, intended to inform dose selection for potential Phase 3 development program; initial clinical data expected in 2H 2026  Recent significant corporate milestones include the selection of a CDMO, CFO hire, and opening of corporate headquarters Cash, cash equivalents and short-term investments of $77.0M as of September 30, 2025, expected to fund operations into 2027 Kalaris is currently evaluating TH103, a dual-targeting biologic designed to achieve superior VEGF inhibition and extended intraocular durability through optimized binding to VEGF receptor 1 ligands and concurrent heparan sulfate proteoglycan (HSPG) anchoring BERKELEY HEIGHTS, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced financial results for the third quarter ended September 30, 2025, and provided business updates.

Highly experienced biopharma financial officer joins leadership team  CFO hire bolsters Kalaris' leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study in treatment naïve nAMD patients PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Matthew Gall, MBA, as Chief Financial Officer.

PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Stifel 2025 Annual Healthcare Conference.

Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial monthly doses of TH103

Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and preliminary efficacy in nAMD patients receiving up to four initial monthly doses of TH103 Phase 1b/2 study to inform dose selection for potential Phase 3 development program, with initial data expected in 2H 2026 TH103's ongoing Phase 1a single ascending dose study remains on track for data to be reported  in Q4 2025 PALO ALTO, Calif., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that it is now enrolling a Phase 1b/2 multiple ascending dose (MAD) study of TH103 in patients with neovascular age-related macular degeneration (nAMD).